Olanzapine Extended Release
TV44749-NPC-10205
Phase 1 small_molecule completed
Quick answer
Olanzapine Extended Release for Schizophrenia, Schizoaffective Disorder is a Phase 1 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Teva Pharma GmbH
- Indication
- Schizophrenia, Schizoaffective Disorder
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed